$320,000 of SAREPTA THERAPEUTICS INC. lobbying was just disclosed, from Q1 of 2025, in a new Lobbying Disclosure Act filing.
This included lobbying on issues like:
"Issues related to patient access to treatments Issues related to rare diseases such as Duchenne Muscular Dystrophy Issues related to newborn screening for rare diseases Issues related to the Inflation Reduction Acts prescription drug provisions Issues related to scientific innovation in healthcare such as gene therapies Issues related to artificial intelligence and data governance Tax issues related to research and development"
You can find more data on corporate lobbying on Quiver Quantitative.
SRPT Insider Trading Activity
SRPT insiders have traded $SRPT stock on the open market 3 times in the past 6 months. Of those trades, 0 have been purchases and 3 have been sales.
Here’s a breakdown of recent trading of $SRPT stock by insiders over the last 6 months:
- HANS LENNART RUDOLF WIGZELL sold 10,500 shares for an estimated $1,310,820
- CLAUDE NICAISE sold 2,491 shares for an estimated $248,203
- KATHRYN JEAN BOOR sold 1,636 shares for an estimated $205,399
To track insider transactions, check out Quiver Quantitative's insider trading dashboard.
SRPT Hedge Fund Activity
We have seen 214 institutional investors add shares of SRPT stock to their portfolio, and 218 decrease their positions in their most recent quarter.
Here are some of the largest recent moves:
- CAPITAL INTERNATIONAL INVESTORS added 2,437,855 shares (+38.9%) to their portfolio in Q4 2024, for an estimated $296,418,789
- UBS GROUP AG added 1,115,826 shares (+306.4%) to their portfolio in Q4 2024, for an estimated $135,673,283
- ECOR1 CAPITAL, LLC added 770,000 shares (+inf%) to their portfolio in Q4 2024, for an estimated $93,624,300
- JACOBS LEVY EQUITY MANAGEMENT, INC removed 753,845 shares (-100.0%) from their portfolio in Q4 2024, for an estimated $91,660,013
- WELLINGTON MANAGEMENT GROUP LLP removed 657,842 shares (-24.1%) from their portfolio in Q4 2024, for an estimated $79,987,008
- ASSENAGON ASSET MANAGEMENT S.A. added 580,123 shares (+438.0%) to their portfolio in Q1 2025, for an estimated $37,023,449
- FMR LLC removed 542,876 shares (-43.9%) from their portfolio in Q4 2024, for an estimated $66,008,292
To track hedge funds' stock portfolios, check out Quiver Quantitative's institutional holdings dashboard.
SRPT Analyst Ratings
Wall Street analysts have issued reports on $SRPT in the last several months. We have seen 5 firms issue buy ratings on the stock, and 1 firms issue sell ratings.
Here are some recent analyst ratings:
- BMO Capital issued a "Outperform" rating on 12/02/2024
- Piper Sandler issued a "Overweight" rating on 11/27/2024
- Needham issued a "Buy" rating on 11/27/2024
- Cantor Fitzgerald issued a "Overweight" rating on 11/07/2024
- Raymond James issued a "Underperform" rating on 10/21/2024
- Jefferies issued a "Buy" rating on 10/21/2024
To track analyst ratings and price targets for SRPT, check out Quiver Quantitative's $SRPT forecast page.
SRPT Price Targets
Multiple analysts have issued price targets for $SRPT recently. We have seen 5 analysts offer price targets for $SRPT in the last 6 months, with a median target of $182.0.
Here are some recent targets:
- Biren Amin from Piper Sandler set a target price of $182.0 on 11/27/2024
- Gil Blum from Needham set a target price of $202.0 on 11/27/2024
- Brian Skorney from Robert W. Baird set a target price of $193.0 on 11/07/2024
- Kristen Kluska from Cantor Fitzgerald set a target price of $167.0 on 11/07/2024
- Andrew Tsai from Jefferies set a target price of $165.0 on 10/21/2024
This article is not financial advice. See Quiver Quantitative's disclaimers for more information.
